Huang, Anliang <br/><br/>
SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.  [electronic resource] 

 -  Oncology reports  Dec 2016 
 - 3283-3290 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-2431 
<br/><br/><label>Standard No.: </label>10.3892/or.2016.5161  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis<br/>Arsenic Trioxide<br/>Arsenicals--administration & dosage<br/>Carcinoma, Hepatocellular--drug therapy<br/>Drug Resistance, Neoplasm<br/>Female<br/>Inhibitor of Apoptosis Proteins--genetics<br/>Liposomes<br/>Liver Neoplasms, Experimental--drug therapy<br/>Membrane Potential, Mitochondrial--drug effects<br/>Mice, Inbred C57BL<br/>Mutation, Missense<br/>Neoplasm Transplantation<br/>Oxides--administration & dosage<br/>Reactive Oxygen Species--metabolism<br/>Repressor Proteins--genetics<br/>Survivin